The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R.sup.1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R.sup.1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R.sup.1 may optionally be substituted; and R.sup.2 is a cyclic group substituted at the α-position, wherein R.sup.2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP.sub.3.

##STR00001##

The present invention relates to compounds of formula (I): ##STR00001##
wherein Q is selected from O or S; R.sup.1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R.sup.1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R.sup.1 may optionally be substituted; and R.sup.2 is a cyclic group substituted at the α-position, wherein R.sup.2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

The invention relates to medicine, in particular to gastroenterology, and lies in the field of treatment of liver diseases of various origins. For this purpose, the hepatoprotective agent that is introduced to the patient is embodied as derivatives of bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl)arylmethanes. The method provides reduction of the manifestations of cytolysis under the influence of damaging agents and a statistically significant reduction of dysproteinemia, it accelerates restoration of detoxifying processes of the liver, increases induction of endogenic interferon alfa and, consequently, makes the protection of liver cells during hepatitides of various origins more effective.

The invention relates to medicine, in particular to gastroenterology, and lies in the field of treatment of liver diseases of various origins. For this purpose, the hepatoprotective agent that is introduced to the patient is embodied as derivatives of bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl)arylmethanes. The method provides reduction of the manifestations of cytolysis under the influence of damaging agents and a statistically significant reduction of dysproteinemia, it accelerates restoration of detoxifying processes of the liver, increases induction of endogenic interferon alfa and, consequently, makes the protection of liver cells during hepatitides of various origins more effective.

The present application provides an electrolyte and an electrochemical device. The electrolyte according to the present application comprises a carboxylate, a barbituric acid compound and a nitrile compound. Adding a barbituric acid compound and a nitrile compound of particular structure to an electrolyte containing a carboxylate solvent can significantly improve the rate performance of an electrochemical device, and mitigate capacity loss after storage at room temperature, and cycle fading and gas generation at high-temperature of the electrochemical device.

The present application provides an electrolyte and an electrochemical device. The electrolyte according to the present application comprises a carboxylate, a barbituric acid compound and a nitrile compound. Adding a barbituric acid compound and a nitrile compound of particular structure to an electrolyte containing a carboxylate solvent can significantly improve the rate performance of an electrochemical device, and mitigate capacity loss after storage at room temperature, and cycle fading and gas generation at high-temperature of the electrochemical device.

The invention relates to a class of 5-carboxamide-2-thiobarbituric acid derivatives which inhibits human type II topoisomerase (topoII) enzyme and to use thereof as medicaments especially for blocking the proliferation of cancer cells and treating cancer. The invention also provides a method for the manufacture of the 5-carboxamide-2-thiobarbituric acid derivatives.

The invention relates to a class of 5-carboxamide-2-thiobarbituric acid derivatives which inhibits human type II topoisomerase (topoII) enzyme and to use thereof as medicaments especially for blocking the proliferation of cancer cells and treating cancer. The invention also provides a method for the manufacture of the 5-carboxamide-2-thiobarbituric acid derivatives.

The present invention relates to compounds of formula (I):

##STR00001##

wherein Q is selected from O or S; R.sup.1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R.sup.1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R.sup.1 may optionally be substituted; and R.sup.2 is a cyclic group substituted at the -position, wherein R.sup.2 may optionally be further substituted.

The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

The present application provides an electrolyte and an electrochemical device. The electrolyte according to the present application comprises a carboxylate, a barbituric acid compound and a nitrile compound. Adding a barbituric acid compound and a nitrile compound of particular structure to an electrolyte containing a carboxylate solvent can significantly improve the rate performance of an electrochemical device, and mitigate capacity loss after storage at room temperature, and cycle fading and gas generation at high-temperature of the electrochemical device.